Zhang RJ - Search Results

1

Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma : A matched-pair multicenter analysis of outcomes.

Dong YY, Xiang C, Lu JX, Su YX, Pan YF, Cai R, Zhang RJ, He ZK, Liu ML, Huang H, Bai X, Tang HY, Shi YH, Wang Y, Jiang W. Dong YY, et al. Among authors: zhang rj. Strahlenther Onkol. 2016 Jun;192(6):394-402. doi: 10.1007/s00066-016-0970-3. Epub 2016 May 23. Strahlenther Onkol. 2016. PMID: 27215563 English.

2

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.

Kong XY, Lu JX, Yu XW, Zhang J, Xu QL, Zhang RJ, Mi JL, Liao SF, Fan JF, Qin XL, Yao DC, Tang HY, Jiang W. Kong XY, et al. Among authors: zhang rj, zhang j. Cancer Chemother Pharmacol. 2019 Jul;84(1):155-161. doi: 10.1007/s00280-019-03858-7. Epub 2019 May 13. Cancer Chemother Pharmacol. 2019. PMID: 31087135 Clinical Trial.

3

Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.

Aftab O, Liao S, Zhang R, Tang N, Luo M, Zhang B, Shahi S, Rai R, Ali J, Jiang W. Aftab O, et al. Radiat Oncol. 2020 Mar 16;15(1):66. doi: 10.1186/s13014-020-01508-4. Radiat Oncol. 2020. PMID: 32178698 Free PMC article.

4

Feasibility and efficiency of double-agent versus single-agent concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.

Qin G, Rai R, Zhang R, Su Y, Zhang B, Pan Y, Xiong R, Xie Y, Yang H, Kong X, Luo Z, Ruan X, Mo Y, Aftab O, Shahisanjeev, Jazib, Jiang W. Qin G, et al. Oral Oncol. 2020 Jul;106:104704. doi: 10.1016/j.oraloncology.2020.104704. Epub 2020 Apr 21. Oral Oncol. 2020. PMID: 32330685

5

Prognostic value of the tumor volume reduction rate after neoadjuvant chemotherapy in patients with locoregional advanced nasopharyngeal carcinoma.

Yang H, Liu Y, Zhang R, Ye Y, Chen Q, Qin Q, Huang L, Li X, Cai R, Tang H, Jiang W. Yang H, et al. Oral Oncol. 2020 Nov;110:104897. doi: 10.1016/j.oraloncology.2020.104897. Epub 2020 Jul 14. Oral Oncol. 2020. PMID: 32679404

6

Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.

Ruan X, Liang JH, Pan Y, Cai R, Zhang RJ, He Z, Yang X, Niu Z, Jiang W. Ruan X, et al. Among authors: zhang rj. Cancer. 2021 Sep 1;127(17):3163-3171. doi: 10.1002/cncr.33626. Epub 2021 May 27. Cancer. 2021. PMID: 34043812 Free article. Clinical Trial.

7

Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.

Yang H, Zhang R, Zhang R, Zhang B, Xie Y, Qin G, Mo Y, Ruan X, Jiang W. Yang H, et al. Strahlenther Onkol. 2022 Sep;198(9):828-837. doi: 10.1007/s00066-022-01926-1. Epub 2022 Apr 6. Strahlenther Onkol. 2022. PMID: 35384452

8

Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.

Liu J, Zhang B, Su Y, Qin G, Kong X, Mo Y, Zhang R, Jiang W. Liu J, et al. Radiother Oncol. 2023 Oct;187:109815. doi: 10.1016/j.radonc.2023.109815. Epub 2023 Jul 20. Radiother Oncol. 2023. PMID: 37480994 Clinical Trial.

9

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.

Mo Y, Pan Y, Zhang B, Zhang J, Su Y, Liu Z, Luo M, Qin G, Kong X, Zhang R, Pan Y, Liang Y, Wang D, Wei Y, Chen H, Jiang W. Mo Y, et al. Front Immunol. 2024 Jan 3;14:1298418. doi: 10.3389/fimmu.2023.1298418. eCollection 2023. Front Immunol. 2024. PMID: 38239359 Free PMC article. Clinical Trial.

10

Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.

Liao S, Zhang B, Su Y, Pan Y, Zhang J, Ye Z, Zhang R, Kong X, Qin G, Mo Y, Ruan X, Liu J, Gan C, Dai J, Zhang R, Luo G, Liao X, Jiang W. Liao S, et al. Strahlenther Onkol. 2024 Feb 7. doi: 10.1007/s00066-024-02201-1. Online ahead of print. Strahlenther Onkol. 2024. PMID: 38324078

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

443 results

Search Page